Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Jenny C. Chang"'
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Virginia G. Kaklamani, Jorge Darcourt, Joe Ensor, Jane L. Meisel, Anna Belcheva, SL Creamer, Jenny C. Chang, Wei Qian, J Zhao, X Li, Polly A. Niravath, T Boone, Roberto R. Rosato, Tejal Patel, Angel Rodriguez, John G. Kuhn
Publikováno v:
Cancer Research. 79:P6-17
Background: We conducted a multicenter, randomized open-label phase II neoadjuvant study of trastuzumab-emtansine (T-DM1), Lapatinib (L) and Nab Paclitaxel (Nab-P) compared to standard of care (SOC) Paclitaxel (Pac), Trastuzumab (T), and Pertuzumab (
Autor:
Sarah L. Creamer, Mary R. Schwartz, Xiaoxian Li, Wei Qian, Polly A. Niravath, Roberto R. Rosato, Tejal Patel, Virginia G. Kaklamani, Jane L. Meisel, Angel Rodriguez, Jorge Darcourt, Jing Zhao, Jenny C. Chang, Anna Belcheva, Toniva Boone, Joe Ensor, John G. Kuhn
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade with ado-trastuzumab emtansine (
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Autor:
Jenny C. Chang
Publikováno v:
Cancer Research. 80:ES11-2
Achieving a pathologic complete response (pCR) after neoadjuvant systemic treatment (NST) is clearly associated with improved survival in breast cancer patients, especially with HER2 and triple negative subtypes. In HER2-positive breast cancer patien
Autor:
Stephen L. Jones, Juan Carlos Nicolas, Polly A. Niravath, Tejal Patel, Jenny C. Chang, X. Xu, S. Manne, Kai Sun, Charles E. Geyer, M. Niravath, Kartik Anand
Publikováno v:
Annals of Oncology. 31:S933
Autor:
José A. García-Sáenz, Monika Patre, J. Xu, Jenny C. Chang, P. Fumoleau, SL de Haas, Miguel Martín, S. A. Limentani, Alexander Strasak, Joan Albanell, J. A. Dewar, Mario Campone
Publikováno v:
Annals of Oncology. 27:1249-1256
Background Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal g
Autor:
G. von Minckwitz, Thomas Boulet, T.P. Mamounas, Max S. Mano, Michael Untch, C. Wiese, C-S Huang, I. Schwaner, Norman Wolmark, Chunyan Song, Jenny C. Chang, Charles E. Geyer, S. Limentani, Thomas Hatschek, Kristina Lübbe, N. Loman, S. Loibl, D. Tesarowski, J-C. Thery
Publikováno v:
Annals of Oncology. 31:S48
Autor:
Rui Zhu, Samuel W. Brady, Stephen T. C. Wong, Dihua Yu, Francisco J. Esteva, Chia-Chi Chang, Qingling Zhang, Kenneth Ellis, Qingfei Wang, William J. Muller, Hai Wang, Ozgur Sahin, Melissa D. Landis, Jenny C. Chang, Preety Priya
Publikováno v:
Cell Research
Combinatorial targeted therapies are more effective in treating cancer by blocking by-pass mechanisms or inducing synthetic lethality. However, their clinical application is hampered by resistance and toxicity. To meet this important challenge, we de
Autor:
J. A. Dewar, Joan Albanell, Monika Patre, Alexander Strasak, M. Martin, Jenny C. Chang, S. A. Limentani, José A. García-Sáenz
Publikováno v:
Cancer Research. 73:P4-12
Introduction Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab, a stable linker, and DM1 (a microtubule inhibitor). T-DM1 prolonged PFS and OS compared with standard therapy in a phase 3 study in patients with human